If approved, the new drug would be sold through the sales channels ... a gene therapy approach for HAE with Orchard Therapeutics. Leniolisib is next in line to tap into Pharming's rare disease ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Leniolisib has been being given a speedy ... effects limiting patients' physical activity or wellbeing. If approved, the new drug would be sold through commercial channels set up by Pharming ...

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...